460 related articles for article (PubMed ID: 30619351)
1. Targeting Costimulatory Pathways in Systemic Sclerosis.
Boleto G; Allanore Y; Avouac J
Front Immunol; 2018; 9():2998. PubMed ID: 30619351
[TBL] [Abstract][Full Text] [Related]
2. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.
Ponsoye M; Frantz C; Ruzehaji N; Nicco C; Elhai M; Ruiz B; Cauvet A; Pezet S; Brandely ML; Batteux F; Allanore Y; Avouac J
Ann Rheum Dis; 2016 Dec; 75(12):2142-2149. PubMed ID: 26912566
[TBL] [Abstract][Full Text] [Related]
3. OX40L blockade protects against inflammation-driven fibrosis.
Elhai M; Avouac J; Hoffmann-Vold AM; Ruzehaji N; Amiar O; Ruiz B; Brahiti H; Ponsoye M; Fréchet M; Burgevin A; Pezet S; Sadoine J; Guilbert T; Nicco C; Akiba H; Heissmeyer V; Subramaniam A; Resnick R; Molberg Ø; Kahan A; Chiocchia G; Allanore Y
Proc Natl Acad Sci U S A; 2016 Jul; 113(27):E3901-10. PubMed ID: 27298374
[TBL] [Abstract][Full Text] [Related]
4. Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.
Orvain C; Cauvet A; Prudent A; Guignabert C; Thuillet R; Ottaviani M; Tu L; Duhalde F; Nicco C; Batteux F; Avouac J; Wang N; Seaberg MA; Dillon SR; Allanore Y
Arthritis Res Ther; 2022 Jan; 24(1):13. PubMed ID: 34986869
[TBL] [Abstract][Full Text] [Related]
5. T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis.
Boleto G; Guignabert C; Pezet S; Cauvet A; Sadoine J; Tu L; Nicco C; Gobeaux C; Batteux F; Allanore Y; Avouac J
Arthritis Res Ther; 2018 Aug; 20(1):197. PubMed ID: 30157927
[TBL] [Abstract][Full Text] [Related]
6. CTLA-4: From mechanism to autoimmune therapy.
Hosseini A; Gharibi T; Marofi F; Babaloo Z; Baradaran B
Int Immunopharmacol; 2020 Mar; 80():106221. PubMed ID: 32007707
[TBL] [Abstract][Full Text] [Related]
7. Targeting T cell costimulation in autoimmune disease.
Stuart RW; Racke MK
Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
9. Early inflammatory players in cutanous fibrosis.
Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
[TBL] [Abstract][Full Text] [Related]
10. T follicular helper-like cells contribute to skin fibrosis.
Taylor DK; Mittereder N; Kuta E; Delaney T; Burwell T; Dacosta K; Zhao W; Cheng LI; Brown C; Boutrin A; Guo X; White WI; Zhu J; Dong H; Bowen MA; Lin J; Gao C; Yu L; Ramaswamy M; Gaudreau MC; Woods R; Herbst R; Carlesso G
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29514998
[TBL] [Abstract][Full Text] [Related]
11. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.
Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T
J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of CTLA-4-Ig in tolerance induction.
Alegre ML; Fallarino F
Curr Pharm Des; 2006; 12(2):149-60. PubMed ID: 16454732
[TBL] [Abstract][Full Text] [Related]
13. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
Yoshizaki A
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis.
Asano Y
J Dermatol; 2018 Feb; 45(2):128-138. PubMed ID: 29226387
[TBL] [Abstract][Full Text] [Related]
16. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.
Akiba H; Oshima H; Takeda K; Atsuta M; Nakano H; Nakajima A; Nohara C; Yagita H; Okumura K
J Immunol; 1999 Jun; 162(12):7058-66. PubMed ID: 10358148
[TBL] [Abstract][Full Text] [Related]
17. Use of biologics and other novel therapies for the treatment of systemic sclerosis.
Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M
Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043
[TBL] [Abstract][Full Text] [Related]
18. B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.
Linsley PS; Greenbaum CJ; Speake C; Long SA; Dufort MJ
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830871
[TBL] [Abstract][Full Text] [Related]
19. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
Hasegawa M; Takehara K
Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
[TBL] [Abstract][Full Text] [Related]
20. Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay.
Cutolo M; Soldano S; Montagna P; Trombetta AC; Contini P; Ruaro B; Sulli A; Scabini S; Stratta E; Paolino S; Pizzorni C; Smith V; Brizzolara R
Arthritis Res Ther; 2018 Jul; 20(1):157. PubMed ID: 30053831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
